Omnicell, Inc. (Nasdaq: OMCL), a leader in pharmacy care innovation, announced the appointment of Nnamdi Njoku as Executive Vice President and Chief Operating Officer, effective October 7, 2024.
In his newly created role, Mr. Njoku will report to Randall Lipps, Omnicell’s chairman, president, CEO, and founder, and will lead the company’s global operations.
With nearly 25 years of experience in global healthcare and medical technology, Mr. Njoku previously served as President of Sports Medicine, Surgical, Upper Extremities, and Restorative Therapies at Zimmer Biomet Holdings, Inc. He also spent over 18 years at Medtronic plc, where he held roles of increasing responsibility, including Senior Vice President and President of the Neuromodulation Operating Unit, overseeing a $2 billion business focused on treating pain and movement disorders through neuromodulation.
“We are thrilled to welcome Nnamdi to Omnicell,” said Mr. Lipps. “He brings a wealth of experience in med tech and a proven track record in driving business operations at scale. His passion for leveraging technology to improve healthcare aligns perfectly with Omnicell’s mission.”
Mr. Njoku expressed his enthusiasm about joining Omnicell, noting the company’s strong history of innovation in medication management. He looks forward to contributing to Omnicell’s continued success in transforming pharmacy care.
Mr. Njoku’s extensive background includes leadership roles at UnitedHealth Group and Deloitte Consulting. He has also served on the boards of community health organizations and earned an MBA from Cornell University and a BA in Business Administration from the University of St. Thomas. He is a Fellow of the Aspen Institute’s Health Innovators Fellowship and a member of the Aspen Global Leadership Network.
Since 1992, Omnicell has been dedicated to transforming pharmacy care through innovative solutions designed to optimize outcomes across all care settings. Their comprehensive portfolio includes robotics, smart devices, intelligent software, and expert services aimed at reducing costs, improving efficiency, and advancing the vision of the Autonomous Pharmacy.
